October 27, 2013 | Israeli company Alcobra Pharmaceuticals, which develops Attention Deficit Hyperactive Disorder (ADHD) treatments, has raised $33 million on a secondary Nasdaq offering. The company raised $25 million on its Nasdaq IPO last May.
Related posts
UN Honors Israeli Food Exec For Sustainability Work
September 26, 2023
Startup Unveils Tech To Speed Up Growth Of Cultivated Meat
September 26, 2023
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Facebook comments